Pharma Co Intermune paya $36.9 million to settle whislteblower suit

Intermune Inc. of California will pay the U.S $36.9 million to settle a False Claims Act case for misleading methods of drug marketing to patients for treatments never approved. The company marketed Actimmune for tretament of idiopathic pulmonary fibrosis which the FDA had not approved . The whistleblower will receive 25% of the settlement.